| Document Date: 2015-01-08 17:30:22
Open Document File Size: 599,71 KBShare Result on Facebook
Company Daiichi Sankyo Inc. / / Country United States / / Event FDA Phase / / IndustryTerm medicinal products / food / / MedicalCondition pneumonia / spinal deformity / Nonvalvular Atrial Fibrillation SAVAYSA / nonvalvular atrial fibrillation / bladder dysfunction / severe mitral stenosis / systemic embolism / ischemic stroke / Carcinogenesis / chronic use / Pulmonary Embolism SAVAYSA / stroke / infectious / compartment syndrome / subarachnoid hemorrhage / numbness / permanent paralysis / deep vein thrombosis / Vein Thrombosis / pulmonary embolism / Atrial Fibrillation / subdural hemorrhage / rash / anemia / Interstitial Lung Disease / / MedicalTreatment fibrinolytic therapy / catheter / catheters / Hemodialysis / Surgery / spinal surgery / / Organization DOSAGE AND ADMINISTRATION / FDA / / Person Bleedingc Intracranial Hemorrhage / MIN SAVAYSA / / / Position physician / Major / / Product Discontinue LMWH / Vitamin K Antagonists Oral / Protamine sulfate / Vitamin K / Discontinue / Rifampin / Oral / SAVAYSA / / ProgrammingLanguage ML / / Technology Pharmacokinetics / Pharmacodynamics / / URL www.fda.gov/medwatch / /
SocialTag |
SAVAYSA (edoxaban) tablets Label